Verici Dx plc (VRCDF)

Market Cap	13.94M +8.8%
Revenue (ttm)	1.91M -55.9%
Net Income	-7.62M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	35,360
Open	0.0030
Previous Close	0.0030
Day's Range	0.0030 - 0.0030
52-Week Range	0.0030 - 0.0400
Beta	1.58
RSI	28.70
Earnings Date	Apr 14, 2026

About Verici Dx

Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. It also offers sequencing services for tumor-only, tumor-normal, and germline exomes; whole transcriptome, targeted RNASeq and ncRNAs, and functiona...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 15
• Stock Exchange: OTCMKTS
• Ticker Symbol: VRCDF

Financial Performance

In 2024, Verici Dx's revenue was $3.34 million, an increase of 229.62% compared to the previous year's $1.01 million. Losses were -$5.87 million, -32.75% less than in 2023.